These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26355062)

  • 21. High-Expenditure Pharmaceutical Use Among Children in Medicaid.
    Cohen E; Hall M; Lopert R; Bruen B; Chamberlain LJ; Bardach N; Gedney J; Zima BT; Berry JG
    Pediatrics; 2017 Sep; 140(3):. PubMed ID: 28765380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical Expenditures Associated With Diabetes Among Adult Medicaid Enrollees in Eight States.
    Ng BP; Shrestha SS; Lanza A; Smith B; Zhang P
    Prev Chronic Dis; 2018 Sep; 15():E116. PubMed ID: 30264691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of Medicare Part D on health care utilization for non-elderly Medicare recipients with disabilities.
    Nelson RE; Nelson SL; Huttner B; Gundlapalli A
    Disabil Health J; 2014 Jan; 7(1):64-9. PubMed ID: 24411509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Who bears the burden of Medicaid drug copayment policies?
    Stuart B; Zacker C
    Health Aff (Millwood); 1999; 18(2):201-12. PubMed ID: 10091449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends in the utilization of, spending on, and prices for outpatient antifungal agents in US Medicaid programs: 1991-2009.
    Desai VC; Cavanaugh TM; Kelton CM; Guo JJ; Heaton PC
    Clin Ther; 2012 Oct; 34(10):2118-2131.e1. PubMed ID: 23031625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utilization, spending, and price trends for benzodiazepines in the US Medicaid program: 1991-2009.
    Gorevski E; Bian B; Kelton CM; Martin Boone JE; Guo JJ
    Ann Pharmacother; 2012 Apr; 46(4):503-12. PubMed ID: 22454448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients.
    Smalley WE; Griffin MR; Fought RL; Sullivan L; Ray WA
    N Engl J Med; 1995 Jun; 332(24):1612-7. PubMed ID: 7753141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can increases in CHIP copayments reduce program expenditures on prescription drugs?
    Sen B; Blackburn J; Morrisey M; Becker D; Kilgore M; Caldwell C; Menachemi N
    Medicare Medicaid Res Rev; 2014; 4(2):. PubMed ID: 24967148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prescription Drug Use and Cost Trends Among Medicaid-Enrolled Children with Disruptive Behavioral Disorders.
    Zhao L; Cross-Barnet C; McClair VL
    J Behav Health Serv Res; 2018 Oct; 45(4):550-564. PubMed ID: 29572707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic catastrophes: exploring the concentration and sustained nature of ambulatory prescription drug expenditures in the population of British Columbia, Canada.
    Hanley GE; Morgan S
    Soc Sci Med; 2009 Mar; 68(5):919-24. PubMed ID: 19135288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current and future forecasts of service use and expenditures of Medicaid-eligible schizophrenia patients in the state of Georgia.
    Miller LS; Martin BC
    Schizophr Bull; 2004; 30(4):983-95. PubMed ID: 15954202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in health care expenditures, utilization, and health status among US adults with spine problems, 1997-2006.
    Martin BI; Turner JA; Mirza SK; Lee MJ; Comstock BA; Deyo RA
    Spine (Phila Pa 1976); 2009 Sep; 34(19):2077-84. PubMed ID: 19675510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimates of pediatric medication use in the United States: current abilities and limitations.
    Lasky T
    Clin Ther; 2009 Feb; 31(2):436-45. PubMed ID: 19302916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utilization, price, and spending trends for antidepressants in the US Medicaid Program.
    Chen Y; Kelton CM; Jing Y; Guo JJ; Li X; Patel NC
    Res Social Adm Pharm; 2008 Sep; 4(3):244-57. PubMed ID: 18794035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Managed care for the Medicaid disabled: effect on utilization and costs.
    Cebul RD; Solti I; Gordon NH; Singer ME; Payne SM; Gharrity KA
    J Urban Health; 2000 Dec; 77(4):603-24. PubMed ID: 11194305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elimination of over-the-counter medication coverage in the Oregon Medicaid population: the impact on program costs and drug use.
    Zechnich AD; Greenlick M; Haxby D; Mullooly J
    Med Care; 1998 Aug; 36(8):1283-94. PubMed ID: 9708599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies used by adults to reduce their prescription drug costs.
    Cohen RA; Kirzinger WK; Gindi RM
    NCHS Data Brief; 2013 Apr; (119):1-8. PubMed ID: 23742848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How does Cash and Counseling affect costs?
    Dale SB; Brown RS
    Health Serv Res; 2007 Feb; 42(1 Pt 2):488-509. PubMed ID: 17244294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Policy Recommendations for Public Health Plans to Stem the Escalating Costs of Prescription Drugs: A Position Paper From the American College of Physicians.
    Daniel H; Bornstein SS;
    Ann Intern Med; 2019 Dec; 171(11):825-827. PubMed ID: 31711137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.